n/a
Article Publish Status: FREE
Abstract Title:

and its ingredient biopterin glucoside improved insulin sensitivity in non-alcoholic steatohepatitis model.

Abstract Source:

J Clin Biochem Nutr. 2021 Sep ;69(2):151-157. Epub 2021 Mar 25. PMID: 34616107

Abstract Author(s):

Yuri Fujihara, Yasumasa Kodo, Shin-Ichi Miyoshi, Ritsuko Watanabe, Hiroshi Toyoda, Mitsumasa Mankura, Hideaki Kabuto, Fusako Takayama

Article Affiliation:

Yuri Fujihara

Abstract:

Non-alcoholic steatohepatitis is the chronic liver disease leading to cirrhosis and cancer and its prevalence is increasing. Some agents are under clinical trials for non-alcoholic steatohepatitis treatment. We previously reportedeffectively prevented non-alcoholic steatohepatitis progression in our model rats. The contribution of phycocyanin, an ingredient of, was limited. We, therefore, have looked for more active components of. In this study, we pursued the effect of biopterin glucoside, another bioactive ingredient of. We foundand biopterin glucoside oral administrations effectively alleviated oxidative stress, inflammation and insulin signal failure, and prevented fibroblast growth factor 21 gene overexpression in non-alcoholic steatohepatitis rat livers. We concluded biopterin glucoside is a major component ofaction.

Study Type : Animal Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.